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DISTINCT TUMOR CELL MEMBRANE CONSTITUENTS ACTIVATE HUMAN 
MONOCYTES FOR TUMOR NECROSIS FACTOR SYNTHESIS 
REINER JANICKE AND DANIELA N. MANNEL 
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Several lines of evidence point to an  activation 
mechanism of monocytes/macrophages by tumor 
cells. In this  study we present  data  for  distinct  sur- 
face  structures  on K562  and  Jurkat cells to directly 
induce TNF-mRNA expression  and TNF production 
by human peripheral blood monocytes. Northern 
analysis showed  that  incubation of monocytes  with 
either  K562  or  Jurkat cells led to a  significant  in- 
crease in TNF-mRNA expression. In addition, en- 
hanced TNF production was detected in superna- 
tants of monocyte cultures activated by Jurkat 
cells. Not only  viable  tumor cells but also metabol- 
ically  inactivated  tumor cells, cytoblasts, and  mem- 
brane  preparations  from  Jurkat  and  K562 cells in- 
duced TNF-mRNA expression. We identified  two  dif- 
ferent membrane protein fractions with relative 
molecular  mass of 32 to 38 kDa  for  Jurkat cells and 
46  to  54  kDa  for  K562 cells that were  responsible 
for  monocyte  activation. 
Considerable evidence suggests that monocytes and 
macrophages play an important role in host defense 
against  tumor  growth (1 -3). Monocytes and  macrophages 
release  inflammatory  mediators  like TNF when  activated 
by bacterial, parasitic, or viral agents. Production and 
release of TNF is one of the cytolytic  effector mechanisms 
by which the activated  monocytes and  macrophages de- 
stroy  certain  neoplastic  cells  in vitro (4, 5). However, it is 
unclear whether monocytes directly respond to tumor 
cells and if so how they  distinguish  between  normal  and 
neoplastic cells. Recent studies demonstrated elevated 
TNF levels in  serum of cancer  patients (6, 7). After  resec- 
tion of the  tumors  the TNF levels returned  to  normal (7). 
In addition, tumor cytostatic activity of monocytes de- 
rived from  cancer  patients  was  enhanced  compared  to 
healthy  controls (8, 9). Since  some  tumor cell lines were 
found  to produce TNF (1 0) these  reports could not  distin- 
guish  whether  enhanced TNF serum levels  were due  to 
TNF released by activated  monocytes/macrophages  or by 
tumor  cells. In this  study we  present  data  that  distinct 
surface structures of tumor cells can directly activate 
human monocytes  for TNF production. We used  two  hu- 
man  tumor cell lines K562, a proerythromyeloid cell line 
and  Jurkat, a T cell line  to  show  increased TNF-mRNA 
and TNF protein  production in  human monocytes  after 
exposure  to  these  cells. Two different  membrane  protein 
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fractions  were  responsible  for  induction of TNF produc- 
tion by human  peripheral blood monocytes, 
MATERIALS AND METHODS 
Culture methods. All cell lines were cultured in RPMl 1640 
(GIBCO. Glasgow, Scotland)  supplemented  with  10%  heat-inacti- 
vated FCS (GIBCO) and 50 pglml  gentamycin (GIBCO). under 5% COz 
in  air  at 37°C. K562, a proerythromyeloide cell line  and  Jurkat. a T 
cell line  were  regularly  tested for Mycoplasma contamination  and 
also  the  absence of viral  structures  was  established  (1  1). 
Mycoplasma test. Mycoplasma growth in culture medium of 
tumor  cells  was  tested  by  spreading it on PPLO' agar (Difco, Detroit, 
MI) supplemented with 20% horse serum and 1% yeast autolysate 
for  10  days at 37°C and 5% COz. Alternatively, the  culture  medium 
was  first  incubated  in PPLO broth  for 7 to  10  days  and  then  spreaded 
on PPLO agar. Mycoplasma growth  in  these  cultures  was  examined 
microscopically. 
England) a t  600 rpm  for 5 min  on  glass  slides,  fixed  for 15  min  in 
In parallel. cells were spun down in a cytocentrifuge (Shandon. 
methanol/acetic  acid 3: 1 and  stained  for 30 min  with  the  fluorescent 
dye  (Hoechst  33258, Riedel de  Haen.  Hannover, FRG) a t  a concen- 
tration of 0.05 to 0.5 pg/ml. The preparations were inspected by 
fluorescence  microscopy. 
isolated  from blood of healthy  donors by density  gradient  centrifu- 
Isolation of monocytes. Human  peripheral blood monocytes  were 
gation  (12).  The  interphase  was  washed  twice  in RPMI 1640  and  the 
Costar  plates (4 X 106/well)  for  dot blot analyses or in  100-mm2  petri 
mononuclear  cells  were allowed to  adhere  for 1  h either  in  24-well 
dishes (6 to 8 X 107/dish) when Northern blotting analyses were 
performed. Contaminating lymphocytes were washed off and  the 
and differential staining) were cultured in RPMI 1640/10% FCS/ 
remaining cells (>95% monocytes as determined by phagocytosis 
gentamycin for the indicated times in the absence or presence of 
various  stimuli. 
L929-Bioassay and TNF-ELISA. The supernatants from acti- 
vated  monocyte  cultures  were collected at the indicated  times and 
stored a t  -20°C until  they  were  assayed  for TNF activity  in the  L929 
bioassay (13) (in the presence of actinomycin D) and  in the TNF- 
specific ELISA system  (14).  In  both  assay  systems  the  absorption 
curves  obtained  with  the  test  samples  were  compared  with a stand- 
ard curve obtained with human rTNF (Knoll/BASF AG, Ludwigs- 
hafen. FRG) and the TNF content expressed as nanograms per 
milliliter. 
Preparation ofcytoblasts. Enucleated  cells  (cytoblasts)  were  pre- 
pared as previously described (15). Briefly. cells  (2 X 107/ml)  were 
suspended  in  12.5% Ficoll 400 (Pharmacia.  Freiburg. FRG) in gra- 
dient medium consisting of PBS, 10 pg/ml cytochalasin B (Sigma, 
Munchen. FRG). 0.5% DMSO, and  10 mM HEPES (pH 7.2).  Aliquots 
Ficoll gradient,  centrifuged a t  25.000  rpm  for 60 min a t  31°C. and 
of 3 ml of the cell suspension were layered onto a discontinuous 
with RPMl 1640  containing  10% FCS. 
the  cytoblasts  were collected from the  interphase  and  washed  twice 
Membrane preparation and electroelution. For  membrane  prep- 
arations  (16).  cells (2 to 4 X 10') were  homogenized  with a Polytron 
homogenizer  in  10 mM sodium  phosphate  buffer (pH 7.4)  containing 
1 mM  MgC1, 30 mM NaCI, 1 mM dithiothreitol, 0.005 mM PMSF, and 
0.1  pglml DNase (without NaN3). The  homogenate  was  layered  onto 
a 41%  solution of sucrose (in PBS) and  centrifuged  at  95.000 X g .  
After 1  h the  white  interfacial  band of membranes  was collected and 
washed  twice  with  homogenization  buffer. 
These  membrane  preparations  were  either  used  directly  for  acti- 
vating  monocytes or analyzed  in a 12.5% SDS-PAGE. After  electro- 
phoresis  the gel was  cut  in  13  to 15 small slices. transferred into 
I Abbreviations used in this paper: PPLO, pleuro pneumonia-like or- 
ganisms: RT. room temperature. 
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dialysis  tubes  containing  1 ml elution  buffer (50 mM Tris,  0.38 M 
glycine. and  0.1% deoxycholate), and  the  proteins  were  electroeluted 
for 1 h at   100 V. The  samples  were dialyzed against PBS and  the 
appropriate  molecular  weight  for  each  fraction  was  determined by 
RNA-Dot blot analysis. RNA-dot blots were performed by the 
guanidine-HC1 method (17). The RNA was blotted on nylon filters 
(Genofit, Heidelberg,  FRG) and hybridized as described (181. 
Northern blot analysis. Cytoplasmic RNA was prepared (19). 
electrophoresed on 1 W agarose/formaldehyde gels, transferred to 
nylon filters and hybridized as previously described (18). A TNF 
cDNA probe  (425-bp  PstI-fragment of the  nontranslated  3”region of 
human TNF) was labeled by the  random  primer  method  (20).  After 
cxposure to x-ray film a t  -7O’C. the  filters  were  stripped  and  hy- 
bridized  for  control  with a human /%actin cDNA probe  (560-bp SalI- 
EcoRI cDNA fragment)  (21). 
In situ hybridization. In situ hybridization was based on the 
method of Haase  et  al.  (22).  Aliquots of 100 pl  of a cell suspension (5 
X 105/ml)  were  deposited  on  precoated  glass  slides by spinning in a 
cytocentrifuge  (Shandon,  England) at 600 rpm  for 5 rnin. After  air 
drying,  the  preparations  were  fixed for 5 min  with  4%  paraformal- 
dehyde  in PBS and  stored at -2OOC in  70%  ethanol.  For  prehybridi- 
ration  the  preparations  were  rehydrated  at  RT  in PBS for 20 min, 
incubated in PBS/5 mM MgC12 (10 min). 0.2 M Tris/O.l M glycine 
(10  min).   and  at  42°C  in  2 x SSC/50%  formamide  (10  min).  The cell 
preparations  were  hybridized  with -1 to 3 ng of probe  (1 x lo6 dpm) 
dATP and 50 pCi of ~ ~ ~ S - l a b e l e d  dCTP (NEN. Dreieich, FRG) in  10 
labeled by the  random  primer  method  with 50 pCi of ~ ~ ~ S - l a b e l e d  
pl of a solution  consisting of deionized 50% formamide/2 X SSC/lO% 
dexran  sulfate/l%  RNase  free BSA (Bohringer.  Mannheim,  FRG)/10 
mM dithiothreitol/sonicated salmon sperm DNA (250 pg/ml) and 
Escherichia coli t-RNA (2 mg/ml). The  solution  was  placed  on  the 
cells and covered with a siliconized glass coverslip, the edges of 
which  were  sealed  with  rubber  cement.  Hybridization  was  carried 
out at 42°C for 16  to  24  h.  Coverslips  were  removed,  the  slides  were 
rinsed in 2 X SSC. and transferred for 20 min to 1 X SSC/50% 
formamide a t  RT.  Subsequent  washings  were  carried  out  at 42°C in 
1 x SSC/50%  formamide  for  2  h  (change  buffer  after  each 30 min) 
and 5 to 10 min a t  RT in  1 x SSC. The  preparations  were  dehydrated 
through  70%  and 95% ethanol  containing  0.3 M ammonium  acetate. 
For  autoradiography,  slides  were  dipped  into Kodak NTB-2 nuclear 
track  emulsion,  dried  in an upright  position, and  stored  in a light- 
proof box at  4°C for 10 to 15 days. The slides were developed in 
Kodak D-19 developer at 15°C for 3 min  and  stained  with  the Diff- 
quick  solutions (Merz and Dade. Basel.  Switzerland). 
12 .59  SDS-PAGE. 
RESULTS 
To test  whether TNF is involved in immune surveil- 
lance, we investigated  whether  tumor  cells could directly 
induce TNF production by human monocytes.  With  both 
TNF detection  systems,  the  bioassay  for TNF cytotoxic 
activity, as well as the TNF-specific ELISA, significant 
TNF activity and protein was detected in  culture  super- 
natants of monocytes  stimulated  with  Jurkat  cells  (Table 
I). Optimal TNF release in monocyte/Jurkat cell cocul- 
tures  was obtained at a  producer:activator  ratio of 5: 1. 
Significant TNF levels  were  detected as early as 2  h after 
stimulation  and  reached a maximum  after 8 to  12 h (data 
not  shown).  Surprisingly,  in  supernatants of monocyte 
cultures  stimulated  with  K562  cells,  no TNF was  meas- 
ured  (Table I). An explanation  for  this  seeming  lack of 
TNF secretion could be that TNF receptors present on 
K562  cells (23)  in a relatively  high number  (2  to 3X103/ 
cell)  might absorb TNF from  the  supernatant. In agree- 
ment  with  this  hypothesis it was  found  that  increasing 
numbers of K562 cells progressively reduced LPS-in- 
duced TNF levels (Table I). Reduced TNF levels  were not 
observed  when  glutaraldehyde-fixed  K562  cells  saturated 
with TNF were  cultured  with LPS-activated monocytes 
(data  not  shown).  Furthermore,  K562  cells  also  absorb 
rTNF from  culture  dishes  [data  not  shown).  On  the  other 
hand,  when  Jurkat cells  which  express  few TNF recep- 
tors  (2  to 3 X  102/cell) (24) were added to LPS-activated 
monocytes even an  enhanced TNF production was de- 
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TABLE I 
TNF leuels in human monocyte cultures  stimulated by tumor cells 
with or without LPS“ 
Activity (ng/ml TNF) 
Stimulus Cell No. No LPS With LPS (10 #g/ml] 
Bioassayb ELISAC Bloassavb ELISA‘ 
Control 
K562 
K562 
K562 
K562 
Jurkat 
Jurkat 
Jurkat 
Jurkat 
PBL 
3 x 104 
1 x lo4 
3 X lo5 
1 X lo5 
3 X lo4 
1 x 104 
3 X lo5 
1 X lo5 
1 X lo5 
<1 
<1 
<1 
<1 
<1 
<1 
20 
10 
5 
<1 
<1 
<1 
<1 
<1 
<1 
1 
2.5 
20 
5 
<1 
10 
10 
5 
2.5 
1.25 
10 
10 
10 
20 
10 
10 
10 
10 
5 
2.5 
10 
10 
10 
10 
10 
~ ~ ~ ~ 
presence of LPS (Salmonella minnesota) together with tumor cells. The 
“Monocytes (4 to 8 x 1O5/culture] were cultured in the absence or 
TNF protein as described in Materials and Methods. 
supernatants were collected after 16 h  and assayed for TNF activity and 
Experiment 2. 
Experiment 1. 
tected  (Table I). These  data  support  the  assumption  that 
released TNF in  monocyte/K562  cultures  was  absorbed 
by TNF receptors  on  K562  cells. 
TNF protein  detected  in  culture  supernatants of human 
monocytes  activated  with  Jurkat cells was produced by 
the monocytes and  not by contaminating T cells or NK 
cells as shown  in  Table 11. The indicated cell fractions 
were either stimulated with 50 pg/ml Staphylococcus 
aureus or not. A population enriched for monocytes 
(>95%) and  also  the  unfractionated  peripheral blood lym- 
phocytes (PBL including monocytes) activated with S. 
aureus showed  equally  high TNF titers (40 to 80 ng/ml) 
in  the  culture  supernatants. No TNF was  detected  when 
the cells were not activated by S. aureus. In contrast, 
even  after  stimulation  with S. aureus the  nonadherent 
PBL fraction (depleted of monocytes) was not able to 
produce TNF protein. Under those experimental condi- 
tions  only  monocytes  and  not T  cells  or NK cells  were the 
source of TNF. 
To investigate the  findings of tumor cell-induced TNF 
on TNF-mRNA level, human monocytes  were  cultivated 
either with K562 or Jurkat cells for 2 h. Subsequent 
Northern blotting analyses revealed that cells of both 
tested tumor cell lines provided activation signals for 
human monocytes. Significant increase of TNF-mRNA 
expression was observed when monocytes were culti- 
vated  with  Jurkat  cells (Fig. lB, lane 2;  see  also Fig. 2, 
lane 2) as well as with  K562  cells [Fig. l A ,  lane 3). Both 
tumor cell lines  alone failed  to express TNF-mRNA (Fig. 
l A ,  lanes 4 and 5 for K562 cells; Fig. 18 ,  lane 5 for 
Jurkat cells).  Treatment  with  either PMA or TNF of the 
tumor  cells did not lead  to TNF-mRNA expression  (data 
not  shown).  Taken  together,  these  data  indicated  that  not 
only Jurkat cells  but  also  K562  cells were able  to  induce 
TNF synthesis by human monocytes.  Furthermore, Raji 
cells, another lymphoid cell line  and  melanoma  cells  were 
found  to  induce TNF expression  in  monocytes  (data  not 
shown). Therefore, it seems likely that  tumor cell me- 
diated  monocyte  activation is not  restricted  to only  a  few 
tumor cell lines. 
To investigate whether viable cells are required for 
monocyte activation,  tumor  cells  were metabolically in- 
activated by UV-irradiation and tested  for  their  ability  to 
induce TNF-mRNA in monocytes. Figure 1B. lane 3, 
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TABLE 11 
Monocytes as the  source of TNF" 
TNF (ng/ml) 
Cells ELlSA Bioassay 
No stlmulus S. aureus. 50 p d m l  No stimulus S. aureus. 50 pg/ml 
Monocytes <1 40 <1 80 
PBL (unfractionated] 1.25 40 <1 80 
PBL (depleted of monocytes) <1 5 <1 <1 
The 8 x lo5 monocytes  (adherent  cells], 4 x lo6 unfractionated PBL [containing  approximately 8 X lo5 monocytes), 
and  the  nonadherent  fraction of 4 x lo6 PBL (monocyte  depleted] were cultured  in  the  absence or presence of 50 pglrnl 
fixed S. aureus.  The  culture  supernatants were collected after 16 h  and  assayed for TNF activity and TNF protein as  
indicated. 
shows  that  even UV-irradiated Jurkat cells  were  able  to 
induce TNF-mRNA in the monocytes. Cocultivation of 
viable Jurkat cells  with  UV-irradiated  monocytes in con- 
trast did not  lead to TNF-mRNA expression  (Fig. lB,  lane 
To determine on a  single cell level TNF-mRNA expres- 
sion in human monocytes after activation with tumor 
cells,  in  situ  hybridizations  were  performed.  Tumor  cells 
were cultivated with unfractionated PBL under non- 
adherent  conditions.  These cell mixtures  were  used  for 
in  situ  hybridizations. Figure 2, A and B (PBL/K562 cell 
cocultures)  show  that  cells  in  these  cultures  expressed 
significant TNF-mRNA levels. Similar results were ob- 
tained  when  PBL/Jurkat  cocultures were  used for  in  situ 
hybridizations  (data  not  shown). Both types of tumor  cells 
did not show any positive hybridization signal which 
confirms  the  results of Figure 1.  Furthermore,  Figure  2B 
shows  that only a small  percentage of the cells  which by 
morphology looked like monocytes produced the TNF- 
mRNA. These  findings  are  in  agreement  with  our  results 
obtained  with the PMA-activated promyeloid tumor cell 
line HL60 where only 10 to 20% of the cells showed 
positive signals  for TNF-mRNA expression  under  in  situ 
hybridization  conditions  (data  not  shown). 
The specificity of tumor cell mediated  monocyte  acti- 
vation  was  tested by a coculture of monocytes  with allo- 
geneic PBL. As Figure 3 ,  lane 3, shows  these PBL only 
led to a slight  increase  in TNF-mRNA expression in  this 
experiment,  which could be  due  to  contaminating mono- 
cytes  in  the PBL preparation. In five other  independent 
experiments, no enhancement of TNF-mRNA was  seen 
with  allogeneic PBL. Moreover, no TNF protein was de- 
tected  in  supernatants of monocytes  cultured  in  the  pres- 
ence of PBL (Table I). When various Ag-specific T cell 
clones were  investigated  for  monocyte  stimulating  capac- 
ity, it  was  found  that  two of three  clones led to a slight 
increase  (1.5-fold)  in TNF-mRNA expression.  Therefore, 
it  seems possible that  the ability  to  stimulate  monocytes 
for TNF expression  might  not only be restricted  to  tumor 
cells  but  may  be a quality of proliferating  cells.  Further- 
more, monocytes were cultured in cell free tumor cell 
supernatant to  test  whether  soluble  products  from  the 
tumor cells caused the observed monocyte activation. 
Neither enhanced TNF-mRNA levels nor soluble TNF 
protein  was  detected  in  such  cultures  (data  not  shown). 
Taken  together,  these  results  demonstrate  that  the ob- 
served TNF-mRNA was  expressed  in  monocytes  and  not 
in tumor cells cocultured with monocytes and further 
suggests  that  surface  structures on the  outer  membrane 
of the  tumor cells might provide activation signals for 
human monocytes. 
To further  support  the  hypothesis of tumor cell surface 
4). 
structures  which  account  for monocyte activation,  enu- 
cleated  tumor  cells  and  tumor cell membrane  prepara- 
tions  were  prepared.  These  cytoblasts  represent  spheres 
similar  to  the original  cells but  without  nuclei.  They  are 
enclosed by the  intact cell membrane  outside  facing  out. 
Figure 3, lanes 4 and 5, show  that  these  tumor  cytoblasts 
induced  enhanced TNF-mRNA production  compared  with 
untreated  monocytes (Fig. 3, lane 1). Furthermore, mono- 
cytes  also  respond  to  membrane  preparations  from  tumor 
cells  with TNF-mRNA expression (Fig. 3. lane 6). indicat- 
ing  the possibility that isolated surface  structures  might 
cause  this  effect. 
To characterize  these  structures  Jurkat  and allogeneic 
PBL cell membrane  preparations  were  size  fractionated 
on PAGE. Human  monocytes  were  treated  with  the  eluted 
protein  fractions. TNF-mRNA expression  was  deter- 
mined by RNA preparations of the  stimulated  cells  and 
subsequent RNA-dot blot analyses (Fig. 4a).  Stimulation 
of TNF release was analyzed by assaying  the  superna- 
tants  for TNF protein  (Fig.  4b). As shown  in  Figure  4a, 
monocytes  cultured  with  protein  fractions of relative mo- 
lecular mass 32 to 38 kDa  from Jurkat cells  expressed 
enhanced TNF-mRNA levels. Control protein fractions 
from PBL had  no  effect. In addition,  the  supernatants of 
the corresponding  cultures  obtained  significant TNF pro- 
tein (Fig. 4b). Besides the  32- to  38-kDa  protein  fractions 
from Jurkat cells a 77-kDa  protein  fraction  also  induced 
TNF production  (Fig.  4b)  in  human  monocytes. TNF pro- 
tein  induction  after  stimulation  with  the  77-kDa  protein 
fraction was reproducible, whereas TNF-mRNA induc- 
tion  with  the  77-kDa  fraction could be  observed  only in 
some  experiments. 
Comparable  results  were  obtained  when  the  same  ex- 
periment  was  performed  with  K562 cell membrane frac- 
tions. However, the  46-  to  54-kDa  protein  fractions  were 
identified as monocyte-activating  preparations. TNF pro- 
tein  and TNF-mRNA were  induced by the  same  fractions 
(Fig. 4, a and b). Protease  treatment of these  fractions 
abrogated monocyte activation capacity, indicating the 
protein nature of these tumor cell-derived membrane 
structures (data not shown). The observation that  the 
surface  structures  from K562 and  Jurkat cells  which  are 
responsible  for  monocyte  activation  differ  in  their molec- 
ular  mass might  be  due  to  tumor  heterogeneity. 
DISCUSSION 
Although several reports demonstrated elevated TNF 
levels in  serum of cancer  patients  (6,7) no proof could be 
obtained  that  monocytes/macrophages  respond  directly 
to  tumor cells with TNF production.  Besides  monocytes/ 
macrophages  also T and NK cells (24,  25)  and a variety 
of tumor  cells (10) are  able  to produce TNF. Therefore, 
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1 2 3 4 5  
'p . . "
c D N A  probe 
28s- 
18s- TNF 
O-Actin 
c D N A  probe 
28S- 
Figure 2. In situ hybridlzation of K562-actlvated human PBL lympho- 
cytes (with  the TNF-cDNA probe). 2 h  after  onset of Induction (A) X 1000 
and (B) x 400. 
has been  demonstrated  in  situ by Beissert et al. (26)  in 
tumor  infiltrating  macrophages  in  coloncarcinoma biop- 
sies. 
When human monocytes were cultured  together  with 
either K562 or Jurkat cells  for  2 h a significant  increase 
of TNF-mRNA was observed (Fig. 1). The TNF-mRNA was 
exclusively produced by the monocytes and not by the 
tumor  cells as shown  in control  experiments.  Firstly,  both 
tumor cell lines alone did not  express  the TNF-mRNA 
B-Actin (Fig. 1). Also neither PMA nor TNF activation lead to any 
TNF-mRNA signal  in  these  tumor  cells as  determined by 
T N F  
Flgure 1.  Northern blot analysls of human  monocytes treated for 2 h. dot blot analGes  (data not shown). Secondly, not only 
a. With culture medium alone ( lane I]; 10 pdml fixed S. aureus  (Pansor- viable  tumor  cells but  also UV-irradiated tumor  cells (Fig. 
bin, Calbiochem) as  a positive control-for TCF-mRNA expresslon ( lane 2); 1). cytoblasts and even  membrane  preparations (Figs. 3 
and  1x10' K562 cells. respectively (wlthout monocytes). b. With culture and 4, from both lines were to induce 
5x106 K562 cells ( lane 3). Lunes 4 and 5 represent mRNA from 3x10' 
medlum alone ( lane I): 5x10' Jurkat cells ( lane 2); 5x10' UV-irradiated TNF-mRNA expression  in  human monocytes. And fi- 
Jurkat Cells ( lane 3). For control. monocytes were UV-Irradiated and nally,  in situ hybridizations showed that only  monocytes 
treated for 2 h with 5 x  10' viable Jurkat cells ( lane 4). Tumor cells were 
washed off before mRNA extraction ( lanes 2 to 4). Lane 5 represents and not the tumor expressed the TNF-mRNA (Fig* 
mRNA  from 5XlO'Jurkat cells (wlthout monocytes). 2). The fact that only a small proportion of cells showed 
positive hybridization  signals could be  explained by our 
these  studies could not  identify the cellular origin of the 
observed TNF activity. The  results  presented  here dem- 
onstrate  that both  tested  tumor cell lines K562 and  Jur- 
kat provide direct activation signals for human mono- 
cytes  on the  surface of their  outer  membranes  in vitro. 
In addition to the two tumor cell lines used for the 
experiments described above we found two additional 
tumor  lines, Raji. another lymphoid cell line, and mela- 
noma cells with the capacity to  induce TNF-mRNA 
expression  in human monocytes. Recently, TNF-mRNA 
own  unpublished  data.  Even  in the cloned myeloid cell 
line HL60 only 10 to 20% of the cells  expressed the TNF- 
mRNA after  activation by 10 ng/ml PMA as  detected by 
in  situ hybridizations. 
Also the possibility that contaminating  lymphocytes  (T 
cells and NK cells) rather  than monocytes might  be the 
source of tumor cell-stimulated TNF could be excluded. 
Only the  adherent monocyte population and unfraction- 
ated PBL (including  monocytes) were able  to  produce TNF 
protein after  activation by S.  aureus [Table 11). No TNF 
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Figure 3. Northern  blot analysis of human monocytes treated for 2 h 
allogeneic peripheral  blood lymphocytes (lane 3): 3X1O6 K562-cytoblasts 
(lane 4): 9 x 1 0 6  K562-cytoblasts (lane 5) and with a K562-membrane 
preparation (lane 6) .  
could  be detected in culture  supernatants of monocyte- 
depleted nonadherent PBL even after  the activation by s. 
aureus (Table 11). In addition, NK-sensitive targets  such 
as K562 cells were not killed  by stimulated  cultures that 
produced TNF (data not shown). 
When the  supernatants of tumor cell-activated mono- 
cytes were harvested and assayed for TNF activity in the 
L929 bioassay and  in  the TNF specific ELISA system, 
only the activation with Jurkat cells led to  significant 
TNF release by the monocytes. No soluble TNF activity 
could be observed when K562 cells were used (Table I). 
Earlier  experiments by Uchida et  al. (27) have  shown that 
K562 cells induced a monocyte derived cytotoxic factor 
only when the tumor cells were cultured  together  with 
the monocytes on autologous serum-precoated plastic 
dishes. When FCS-precoated plastic  dishes were used.  no 
monocyte cytotoxic factor  was observed. However, in  our 
hands  under identical experimental  conditions  with 
autologous serum-coated  dishes  no TNF release could be 
measured (data not shown). The hypothesis that TNF 
receptors  present in a relatively high number  on K562 
cells (2 to 3 X  103/cell) but  not  on Jurkat cells (2 to 3 X  10') 
( 1  0) might rapidly absorb released TNF from the  super- 
natant was  consistent with our  findings that increasing 
numbers of K562 cells progressively reduced LPS-in- 
duced TNF levels (Table I). This  was not observed when 
Jurkat cells were cultured  together  with LPS-activated 
monocytes. This  hypothesis  was  also  supported by the 
findings that TNF-saturated glutaraldehyde-fixed K562 
cells did not lead to reduced TNF levels (data not  shown). 
Immunoprecipitations revealed that K562 cells induced 
similar levels of the 26-kDa membrane-bound TNF in  the 
MONOCYTE ACTIVATION 
monocytes as  it was observed with the  Jurkat cells (data 
not shown). Since also the level of recombinant TNF 
added to K562 cultures  was reduced within 16 h  (data 
not  shown) it seems conceivable that TNF receptors on 
K562 cells were responsible for the lack of soluble TNF 
in  the  supernatant of human monocytes activated with 
K562 cells. 
Some viruses, such as  Sendai  virus  (28) of influenza 
virus  (29)  have  also been reported to  induce TNF produc- 
tion in human monocytes. Both tumor cell lines (K562 
and  Jurkat) have been tested regularly for the  absence of 
viral structures  and mycoplasma contamination.  There- 
fore,  neither mycoplasma components nor viral proteins 
seemed to be responsible for the observed monocyte ac- 
tivation. In addition, allogeneic structures as activation 
signals were excluded. Allogeneic PBL from different do- 
nors (with  different HLA-types) were tested for their  abil- 
ity to induce TNF synthesis in human monocytes in six 
independent  experiments. Neither TNF production (Table 
I) nor TNF-mRNA expression (Figs. 3 and  4)  was observed 
after coculture of monocytes with allogeneic PBL in  any 
experiment. However, two of three Ag-specific T cell 
clones led to  a  slight  increase of TNF-mRNA when  cul- 
tured together with monocytes. Even though contami- 
nation was not excluded rigorously in these cells, this 
could indicate that not only tumor cells but proliferating 
cells could have the capacity  to  induce monocyte activa- 
tion. 
The  finding of TNF-mRNA expression in human mono- 
cytes induced by metabolically inactivated tumor cells 
but not by tumor cell supernatants indicated that  the 
monocyte activating structures were exposed on the  sur- 
face of the tumor cells. This hypothesis was confirmed 
by the induction of TNF-mRNA and protein expression 
by tumor cytoblasts and even membrane  preparations 
from tumor  cells (Fig. 3). Two distinct  membrane  frac- 
tions from the tumor cell lines were identified which 
accounted for the observed monocyte activation (Fig. 4). 
LPS contamination of only certain  membrane  fractions 
could be excluded because these  experiments were re- 
peated several times with the same molecular weight 
fractions being positive in  each  experiment.  Therefore, it
is very unlikely that only the  32- to  38-kDa  membrane 
fractions from Jurkat cells and  the  46- to 54-kDa frac- 
tions from K562 cells and no fraction from the PBL 
preparation  was  contaminated by  LPS. Furthermore, pro- 
tease  treatment of the monocyte activating  membrane 
fractions abrogated the activity, indicating the protein 
nature of these  structures. If LPS was  the responsible 
agent  also  the protease-treated  fractions  should be able 
to induce TNF-mRNA expression. 
The  fact  that  these proteins differed in  their molecular 
mass (32-  to  38-kDa for Jurkat cells and  46- to 54-kDa 
for K562 cells) cannot be explained at  the moment and 
might be due to tumor heterogeneity. The Observation 
that besides the 32- to 38-kDa protein fraction from 
Jurkat cells  also a 77-kDa protein induced TNF produc- 
tion in human monocytes could be due to a dimeric 
structure.  Further molecular characterization  studies of 
these activation structures might help to answer the 
question of whether  this  represents  the mechanism by 
which  tumor cells are recognized by monocytes/macro- 
phages and  thus distinguished from normal cells in vivo. 
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human monocytes and (b) TNF protein  release  from human monocytes  after  activation for 2 h  with Jurkat cell (closed  clrcles). K562 cell (triangles). 
Figure 4. Isolated protein fractions from tumor cell membranes induced TNF production in human monocytes. (a) TNF-mRNA expression in 
and allogeneic PBL [squares)  membrane  protein  fractions.  In (a) RNA-dot blots  were  made, hybridized with  the TNF cDNA probe and for control  also 
as hybridization  signal  intensity  in  percent  compared  to a positive control  in  which  the  monocytes  were  treated  with  50 pglml S. aureus for 2 h. In 
with the  @-actin cDNA probe. The  autoradiographs  were  measured  densitometrically  with an  Elscript 400 film scanner  and  each  signal  was  expressed 
(b) TNF protein was determined by the TNF-specific ELISA. 
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